title: Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia.
authors.affiliation: Montefiore Medical Center, North Division, New York Medical College, Bronx, New York, USA. pwiernik@chpnet.org
authors.forename: Peter H
authors.initials: PH
authors.lastname: Wiernik
authors.forename: Mahadi A
authors.initials: MA
authors.lastname: Baig
authors.forename: Sung H
authors.initials: SH
authors.lastname: Lee
authors.forename: Janice P
authors.initials: JP
authors.lastname: Dutcher
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Paietta
authors.forename: Janis
authors.initials: J
authors.lastname: Racevskis
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate